Pedro Beltran

Company: BridgeBio

Job title: SVP

Seminars:

Introducing BBO-8520: A First-in-Class Direct Inhibitor of KRASG12C(ON) that Drives Potent & Deep Anti-Tumor Activity in Cancer Models 11:00 am

Understanding how BBO-8520 directly, potently and completely modifies GTP-bound KRASG12C for powerful anti-tumor effects Examining how direct KRASG12C engagement correlates with inhibition of pERK in KRASG12C mutant models leading to comprehensive inhibition of the RAS pathway Showcasing how BBO-8520 overcomes growth factor driven resistance and slows the emergence of resistance in KRASG12C mutant models enabling…Read more

day: Day One Track A AM